

Raising Standards – Protecting Patients

9 February, 2023

ACCSM Filler Blindness Protocol

Please adapt these recommendations for your own clinic. This is a fluid document, updates may ensue according to research.

Firstly, please watch and become familiar with the following video: see video here.

Remember Filler Blindness is rare:

Filler related blindness is a 1 in 300,000 risk.

Check history of any ocular or visual problems BEFORE filler treatment. Quick clinical check of vision BEFORE filler treatment.

VITAL - Have Hyaluronidase vials in your rooms! 1500 Units of hyaluronidase in the region of the supratrochlear and supraorbital notches/foramina and origin of filler injection, repeating every 30-60 minutes.

Essential Elements of acute protocol as follows:

- 1. Massage Eye
- 2. Brown Paper Bag
- 3. Hyaluronidase
- 4. Ophthalmic referral

See table 1 and Figure below.



Raising Standards – Protecting Patients

ACCSM Filler Blindness Protocol

Table 1: Recommended management of visual disturbance post HA filler.

At presentation:

- Record individual eye vision using written text / Snellen chart on smartphone / laptop
- Check pupil light reflex direct and consensual and check for relative afferent pupillary defect (RAPD)
- Check eye movements and for eyelid ptosis
- Check confrontation visual fields for each eye

After diagnosis, whilst other measures are being prepared:

- Demonstrate to patient and patient to commence ocular massage for five seconds for five minutes
- Hypercapnoea: Rebreathing into a paper bag, limited by symptoms of dizziness
- · Consent patient for hyaluronidase treatment
- Have resuscitation equipment available as hyaluronidase has 0.1% risk of anaphylaxis
- Reconstitute 1500IU Hyaluronidase (Wockhardt) in 1ml bacteriostatic saline. To 0.5ml hyaluronidase solution add 0.5ml saline
 750 IU per ml
- Inject hyaluronidase into area where hyaluronic acid was originally injected and all around angiosome distribution of vessel supply by serial puncture (75IU in 0.1ml up to 1500U for vessel distribution)
- If available: preferably IV rather than oral Acetazolamide (Diamox) 500mg bolus & topical ocular antihypertensives (e.g. beta blocker, iodipine, dorzolamide)
- Call local ophthalmology colleague for help, review and follow-up, and prepare transfer
- · Bring protocol and hyaluronidase for ophthalmologist as may not have

Ophthalmic interventions and others:

- Inferotemporal quadrant retrobulbar hyaluronidase injection 1500IU in 4ml saline with 25G retrobulbar needle [3] for ocular adnexal ischaemia and for attempted vision rescue
- Limbal paracentesis with removal of 0.1-0.2ml of aqueous from anterior chamber (remove the plunger on an insulin syringe to allow passive filling)
- Repeat hyaluronidase to vascular territory hourly till capillary refill time (CRT) less than four seconds (up to four cycles per day)
- Consider:
- 1. Repeat retrobulbar hyaluronidase after repeat retinal observation
- IV heparin / steroid reduce clot formation allowing access of hyaluronidase to HA / reduce retinal oedema
- 3. Hyperbaric oxygen
- 4. Scar management



Raising Standards – Protecting Patients

ACCSM Filler Blindness Protocol

Ophthalmic investigations (but not if delay treatment):

- · Consider neuroimaging with angiography
- · Fundus fluorescein angiography
- OCT and photograph facial skin and eye movements

Extracted from:

https://www.thepmfajournal.com/features/features/post/is-there-a-role-for-retrobulbar-hyaluronidase-in-hyaluronic-acid-vascular-embolism-related-vision-loss




Figure 2: Vision loss and vascular occlusion algorithm.